LDLR Modulator

LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research.

VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR.

LDLR regulator-1 (Compound 7b) is a regulator of the low-density lipoprotein receptor (LDLR), capable of increasing the mRNA expression of LDLR.

VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR.

2-Hydroxyacetaldehyde acts as a ribonucleotide synthesis precursor and a LDL modifier. 2-Hydroxyacetaldehyde specifically targets lysine residues of high-affinity LDL receptors and their apolipoproteins. By blocking the ε-amino groups of apolipoproteins, 2-Hydroxyacetaldehyde prevents receptor recognition, thereby reducing LDL degradation by macrophages. 2-Hydroxyacetaldehyde generates modified LDL, which serves as a probe for investigating non-receptor-dependent catabolic pathways.